BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34071012)

  • 1. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment.
    Gandhi S; Oshi M; Murthy V; Repasky EA; Takabe K
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
    Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
    Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
    Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
    Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
    Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
    Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
    Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
    Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.
    Oshi M; Roy AM; Yan L; Sasamoto M; Tokumaru Y; Wu R; Yamada A; Yamamoto S; Chishima T; Narui K; Endo I; Takabe K
    Am J Cancer Res; 2023; 13(7):3041-3054. PubMed ID: 37559984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).
    Tokumaru Y; Oshi M; Murthy V; Tian W; Yan L; Angarita FA; Nagahashi M; Matsuhashi N; Futamura M; Yoshida K; Miyoshi Y; Takabe K
    Am J Cancer Res; 2021; 11(11):5743-5755. PubMed ID: 34873491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral lymphatic endothelial cell infiltration reflecting lymphangiogenesis is counterbalanced by immune responses and better cancer biology in the breast cancer tumor microenvironment.
    Wu R; Sarkar J; Tokumaru Y; Takabe Y; Oshi M; Asaoka M; Yan L; Ishikawa T; Takabe K
    Am J Cancer Res; 2022; 12(2):504-520. PubMed ID: 35261783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner.
    Gibbs C; So JY; Ahad A; Michalowski AM; Son DS; Li Y
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer.
    Gao H; Tian Q; Zhou Y; Zhu L; Lu Y; Ma Y; Feng J; Jiang Y; Wang B
    Front Immunol; 2022; 13():904418. PubMed ID: 35774776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes.
    Zajac KK; Malla S; Babu RJ; Raman D; Tiwari AK
    Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1779. PubMed ID: 36632988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment.
    Wang Y; Goliwas KF; Severino PE; Hough KP; Van Vessem D; Wang H; Tousif S; Koomullil RP; Frost AR; Ponnazhagan S; Berry JL; Deshane JS
    Lab Invest; 2020 Dec; 100(12):1503-1516. PubMed ID: 32572176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.
    Yang A; Wu M; Ni M; Zhang L; Li M; Wei P; Yang Y; Xiao W; An X
    Breast Cancer; 2022 May; 29(3):468-477. PubMed ID: 35061208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High
    Nelson ED; Benesch MG; Wu R; Ishikawa T; Takabe K
    Am J Cancer Res; 2024; 14(1):227-242. PubMed ID: 38323277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
    Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
    Front Immunol; 2022; 13():859581. PubMed ID: 35795662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.